v3.26.3
Revenue Recognition and Accounts Receivable (Tables)
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
(In millions)
Three Months Ended September 30, 2026
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,184.6 $697.1 $143.5 $436.2 $2,461.4 
Generics1,031.3 5.5 143.6 92.9 1,273.3 
Total Viatris$2,215.9 $702.6 $287.1 $529.1 $3,734.7 
(In millions)
Nine Months Ended September 30, 2026
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$3,375.9 $2,085.1 $426.7 $1,324.6 $7,212.3 
Generics3,054.5 11.4 429.9 282.2 3,778.0 
Total Viatris$6,430.4 $2,096.5 $856.6 $1,606.8 $10,990.3 
(In millions)Three Months Ended September 30, 2025
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,241.3 $612.3 $159.1 $424.1 $2,436.8 
Generics1,014.3 2.9 147.2 146.3 1,310.7 
Total Viatris$2,255.6 $615.2 $306.3 $570.4 $3,747.5 
(In millions)Nine Months Ended September 30, 2025
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$3,382.5 $1,751.6 $461.4 $1,242.7 $6,838.2 
Generics2,884.1 8.0 426.7 402.7 3,721.5 
Total Viatris$6,266.6 $1,759.6 $888.1 $1,645.4 $10,559.7 
The following table presents net sales on a consolidated basis for select key products for the three and nine months ended September 30, 2026 and 2025, respectively:
Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Select Key Global Products
Lipitor ®
$451.9 $396.1 $1,366.1 $1,172.0 
Norvasc ®190.2 179.7 600.4 534.7 
EpiPen® Auto-Injectors155.8 157.2 386.1 390.7 
Lyrica ®114.2 126.5 355.4 367.2 
Creon ®98.1 93.1 292.9 266.9 
Viagra ®94.1 105.2 302.0 304.0 
Zoloft ®
78.8 66.8 222.8 188.1 
Celebrex ®
70.2 73.3 213.7 206.7 
Effexor ®
63.9 67.2 192.6 189.6 
Xalabrands43.9 38.6 121.9 116.4 
Select Key Segment Products
Influvac ®$90.6 $125.4 $100.5 $130.8 
Yupelri ®71.5 71.4 204.7 196.3 
Xanax ®36.6 34.2 109.5 100.4 
Amitiza ®36.4 40.8 109.8 115.7 
Dymista ®35.4 33.8 112.5 125.0 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Amounts include the impact of foreign currency fluctuations compared to the prior year period.
(d)Refer to intellectual property matters included in Note 18 Litigation for additional information regarding Amitiza®.
Disaggregation of Revenue, Variable Consideration
The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2026 and 2025, respectively:
Three Months EndedNine Months Ended
September 30,September 30,
(In millions)
2026
202520262025
Gross sales$5,860.1 $6,208.3 $17,863.3 $17,753.3 
Gross to net adjustments:
Chargebacks(1,043.9)(1,265.9)(3,383.8)(3,684.5)
Rebates, promotional programs and other sales allowances(878.9)(975.0)(2,898.3)(2,864.0)
Returns(49.4)(48.7)(136.3)(150.8)
Governmental rebate programs(153.2)(171.2)(454.6)(494.3)
Total gross to net adjustments$(2,125.4)$(2,460.8)$(6,873.0)$(7,193.6)
Net sales$3,734.7 $3,747.5 $10,990.3 $10,559.7 
___________
(a)Amounts include the impact of foreign currency fluctuations.
Schedule of Accounts Receivable, Net Such allowances were comprised of the following at September 30, 2026 and December 31, 2025, respectively:
(In millions)September 30,
2026		December 31,
2025
Accounts receivable, net$1,154.4 $1,257.4 
Other current liabilities941.9 1,011.2 
Total$2,096.3 $2,268.6 
Accounts receivable, net was comprised of the following at September 30, 2026 and December 31, 2025, respectively:
(In millions)September 30,
2026		December 31,
2025
Trade receivables, net$2,631.4 $2,577.6 
Other receivables489.8 453.7 
Accounts receivable, net$3,121.2 $3,031.3